Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial

AIM: To evaluate the efficacy of iGlarLixi by C‐peptide levels and duration of diabetes in an exploratory analysis of the LixiLan‐G study. METHODS: LixiLan‐G was a 26‐week, randomized, open‐label study in adults with type diabetes (T2D) inadequately controlled while on a glucagon‐like peptide‐1 rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Prato, Stefano, Frias, Juan Pablo, Blonde, Lawrence, Aroda, Vanita R., Shehadeh, Niam, Saremi, Aramesh, Dex, Terry, Niemoeller, Elisabeth, Souhami, Elisabeth, Liu, Minzhi, Rosenstock, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754453/
https://www.ncbi.nlm.nih.gov/pubmed/32323437
http://dx.doi.org/10.1111/dom.14068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754453/
https://www.ncbi.nlm.nih.gov/pubmed/32323437
http://dx.doi.org/10.1111/dom.14068

Ejemplares similares